% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Krau:303198,
      author       = {S. M. Krauß and E. Telzerow and D. Richter and A. S. Moret
                      and M. Rothenberg-Thurley and C. Sauerland and A. Weigert
                      and A. Fraccaroli and J. Tischer and F. Ziemann and K. S.
                      Götze and W. E. Berdel and B. Wörmann and U. Krug and J.
                      Braess and P. Heussner and W. Enard and W. Hiddemann and K.
                      Spiekermann$^*$ and D. Görlich and U. Platzbecker and K. H.
                      Metzeler},
      title        = {{C}lonal hematopoiesis in {AML} long-term survivors: {R}isk
                      factors and clinical consequences.},
      journal      = {HemaSphere},
      volume       = {9},
      number       = {7},
      issn         = {2572-9241},
      address      = {Hoboken},
      publisher    = {John Wiley $\&$ Sons Ltd.},
      reportid     = {DKFZ-2025-01549},
      pages        = {e70183},
      year         = {2025},
      abstract     = {Clonal hematopoiesis (CH) is common in the general
                      population and associated with various health risks, but its
                      prevalence and clinical implications in acute myeloid
                      leukemia (AML) long-term survivors (LTS; ≥5-year survival)
                      are unknown. We analyzed CH in 373 AML-LTS with a median
                      11.6-year follow-up from diagnosis using a sensitive
                      targeted sequencing assay based on single-molecule molecular
                      inversion probes. CH variants were detected in $61.9\%$ of
                      survivors, with $26\%$ having small-clone CH (SC-CH, variant
                      allele frequency (VAF) < $2\%)$ and $35.9\%$ CH of
                      indeterminate potential $(≥2\%$ VAF). CH was more
                      prevalent in survivors treated with chemotherapy only
                      $(75.7\%)$ compared to those who received allogeneic stem
                      cell transplantation (alloSCT, $54.0\%)$ and to age
                      group-matched healthy controls. In chemotherapy-treated
                      survivors, CH prevalence increased with age, whereas in
                      alloSCT recipients, it most closely associated with
                      hematopoietic age (i.e., the sum of donor age and time since
                      transplantation). The variant spectrum also differed by
                      treatment, with TP53 and PPM1D variants being more common in
                      the chemotherapy group. CH variants $≥10\%$ VAF associated
                      with increased risks of diabetes in alloSCT recipients and
                      secondary neoplasms in chemotherapy-treated survivors. This
                      study provides insights into the high prevalence and
                      potential clinical relevance of CH in AML-LTS.},
      cin          = {MU01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40709316},
      pmc          = {pmc:PMC12288099},
      doi          = {10.1002/hem3.70183},
      url          = {https://inrepo02.dkfz.de/record/303198},
}